JO
TCRX icon

John Overdeck’s TScan Therapeutics TCRX Stock Holding History

John Overdeck’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
1,949,604
+740,595
+61% +$789K ﹤0.01% 3029
2026
Q1 		$1.22M Buy
1,209,009
+557,830
+86% +$596K ﹤0.01% 3108
2025
Q4 		$651K Buy
651,179
+231,775
+55% +$335K ﹤0.01% 3171
2025
Q3 		$763K Buy
419,404
+54,370
+15% +$96.3K ﹤0.01% 2752
2025
Q2 		$529K Buy
365,034
+274,833
+305% +$397K ﹤0.01% 2562
2025
Q1 		$124K Buy
+90,201
New +$195K ﹤0.01% 2934
2024
Q4 		– Sell
-15,745
Closed -$78.4K – 3477
2024
Q3 		$78.4K Buy
+15,745
New +$95K ﹤0.01% 2921
2024
Q2 		– Sell
-37,747
Closed -$300K – 3326
2024
Q1 		$300K Buy
+37,747
New +$237K ﹤0.01% 2561
2021
Q4 		– Sell
-22,817
Closed -$190K – 4877
2021
Q3 		$190K Buy
+22,817
New +$212K ﹤0.01% 3975

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

John Overdeck's TCRX Position: Q2 2026 in Review

John Overdeck increased its TScan Therapeutics (TCRX) stake by 61% in Q2 2026, buying an estimated $789K and bringing the position to 1,949,604 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #3029.

John Overdeck first reported a position in TCRX in Q3 2021 and has held it in 9 quarters since. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • John Overdeck held 1,949,604 shares of TScan Therapeutics worth $1.91M as of Q2 2026.
  • John Overdeck bought 740,595 TScan Therapeutics shares in Q2 2026, an estimated $789K.
  • TScan Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3029 holding.
  • John Overdeck first reported a position in TScan Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.